2024 NCCN Prostate Cancer Guidelines: Updates in M1 CSPC Treatment - UroToday
Rashid Sayyid and Zachary Klaassen discuss 2024 NCCN prostate cancer guideline updates for systemic therapy in metastatic hormone-sensitive prostate cancer (mHSPC), emphasizing treatment stratification by disease volume and timing. They cover clinical trials supporting triplet therapy for high-volume synchronous disease, like ARASENS and PEACE-1, and different treatment approaches for various patient subgroups. The role of prostate radiotherapy in low-volume synchronous mHSPC is reviewed, along with the expanding use of stereotactic body radiation therapy (SBRT) for oligometastatic disease. The discussion concludes with a personalized treatment paradigm considering both disease volume and timing in mHSPC management.
Reference News
Rashid Sayyid and Zachary Klaassen discuss 2024 NCCN prostate cancer guideline updates for systemic therapy in metastatic hormone-sensitive prostate cancer (mHSPC), emphasizing treatment stratification by disease volume and timing. They cover clinical trials supporting triplet therapy for high-volume synchronous disease, like ARASENS and PEACE-1, and different treatment approaches for various patient subgroups. The role of prostate radiotherapy in low-volume synchronous mHSPC is reviewed, along with the expanding use of stereotactic body radiation therapy (SBRT) for oligometastatic disease. The discussion concludes with a personalized treatment paradigm considering both disease volume and timing in mHSPC management.